Clinical Trials Logo

Clinical Trial Summary

In colorectal surgery, oxygen insufflation (which leads to higher oxygen concentration in the surgical site) has been shown to decrease infection rate. Several pressure wounds in the coccyx have been successfully treated to closure with Transdermal Continuous Oxygen Therapy (TCOT) Given the wound healing properties of TCOT, particularly in infection-prone anatomic locations such as coccyx, and the microbicidal properties of oxygen, it is expected that the infection rate in abdominoperineal (AP) resection surgery can be reduced with transdermal continuous oxygen therapy. The primary objective of this study is to compare the number of surgical site infections associated with perineal surgery within 28 days between subjects randomized to receive EPIFLO or Standard of Care


Clinical Trial Description

EPIFLO is a Small, silent disposable, battery-operated oxygen concentrator capable of delivering 98% to 100% oxygen (balance moisture) for seven days at a rate of ~3.0 ml/hour; and 60" long sterile cannula (tube) that conveys the oxygen concentrator to the area beneath the bandage overlying the wound.

The primary objective of this study is to compare the number of surgical site infections associated with perineal surgery within 30 days between subjects randomized to receive EPIFLO or Standard of Care. Secondary Study objectives include Resource utilization and duration of hospitalization.

Hypothesis 1: The proportion of surgical site infections will be lower for patients treated with Transdermal Continuous Oxygen Therapy (TCOT) Hypothesis 2: In the patients who develop infections, wounds will be smaller and heal more rapidly in those treated with Transdermal Continuous Oxygen Therapy.

Key Safety Assessments Include potential dermatological toxicity changes attributed to EPIFLO as measured by observed and reported discomfort and changes in skin during and after the Treatment Period (It is essential to establish the difference between toxicity from the dressing vs. toxicity arising out of EPIFLO).

This Study will be a randomized controlled trial of 30 patients aged 18-80 years who are scheduled to undergo elective perineal resection surgery at the University of Maryland Medical Center. This study is designed to be a Phase II safety & efficacy study. Patients who met the inclusion/exclusion criteria will be randomized to receive the interventional device with Standard of Care or Standard of Care only (1:1). The patients will be equally divided between the two arms. Sham devices are not involved in this study. Wound infections will be diagnosed by the investigator using Centers for Disease Control and Prevention Criteria. As an additional measure to prevent bias, the pictures of the wounds may be sent to an independent clinical specialist for assessment of infection; this specialist will be blinded to get an objective opinion.

The expected time on study is 1 month ( 27-30 days). This does not include screening period which occurs when the subject consents to be in the study (signs the informed consent) to when they have their surgery (day 1). The screening period can be up to 28 days. While in the study, there are four study visits: Visit 1 day 1 is the day of the surgery, and randomization. The second study visit will be the day of the post surgery discharge (day 3-5). The third study visit will be 14 days following surgery, (day 14) and the Final study visit will be the day of the post surgical follow up visit (day 28). The total treatment period may be 14 or 28 days. After 14-days of treatment, if the wound is completely healed, the treatment phase is complete. If the wound is not completely healed they will receive an additional 14 days of treatment. Either way the patient's healing progress will be followed for a total study duration of 30 days. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention


Related Conditions & MeSH terms


NCT number NCT02374294
Study type Interventional
Source Ogenix Corporation
Contact
Status Withdrawn
Phase Phase 2
Start date September 2015
Completion date September 2015

See also
  Status Clinical Trial Phase
Recruiting NCT02789579 - The Preventive Infection Role of One Week Antibiotics Before Minimally Invasive Upper Tract Lithotomy Early Phase 1
Completed NCT02252562 - Hand Hygiene and Hospital Acquired Infections N/A
Completed NCT01757704 - Factors Responsible for the Effectiveness of the Lund De-airing Technique N/A
Recruiting NCT05005117 - Laparoscopic Approach for Emergency Colon Resection N/A
Enrolling by invitation NCT03234543 - Remote Ischemic Conditioning in Abdominal Surgery N/A
Completed NCT04849702 - Comparison of the Clavien-Dindo and Comprehensive Complication Index
Completed NCT04120324 - Incidence of 30 Day Return to Hospital Following Same Day Discharge Total Hip Arthroplasty
Not yet recruiting NCT06199401 - Safety and Efficacy of XJ-Procedure in Patients With Acute Type A Aortic Dissection Surgery N/A
Recruiting NCT05761821 - Key Factors of Leadless Pacemaker Implantation With Implantation Site, Complications and Prognosis
Active, not recruiting NCT05795127 - Risk for Reoperation After First MTP Joint Arthrodesis
Completed NCT04550156 - Evaluation of the Introduction of a Colorectal Bundle in Left Sided Colorectal Resections N/A
Recruiting NCT05194943 - Trends and Safety in Revisional Bariatric Surgery in Italy
Not yet recruiting NCT03313986 - Outcomes of Surgical Correction of Penile Curvature in Adult N/A
Enrolling by invitation NCT04456530 - Use of Testosterone to Prevent Post-Surgical Muscle Loss - Pilot Study Phase 2/Phase 3
Completed NCT03125798 - Comparison of LigaSure to Conventional Electrocoagulation in Video-assisted Thoracoscopic Surgery Lobectomy N/A
Completed NCT04226482 - Review of Efficacy of Used ultraSonic Energy Device N/A
Completed NCT01739374 - Efficacy and Safety of Reduced Pelvic Floor Mesh Implants Phase 2/Phase 3
Completed NCT01346709 - Prospective Evaluation of a RIsk Score for Postoperative Pulmonary COmPlications in Europe
Enrolling by invitation NCT06394908 - Registry of MIUS for Urolithiasis (ReMIUS-U)
Recruiting NCT02212054 - A Trial on Treatments of Hirschsprung Allied Disease N/A